ARTV

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company founded in 2019 and headquartered in San Diego, California. The company specializes in developing innovative cell-based therapies using natural killer (NK) cells to treat both autoimmune diseases and various forms of cancer. Since its incorporation, Artiva has focused on advancing a pipeline of off-the-shelf and engineered NK cell therapies, with its lead candidate AB-101 currently in clinical development for multiple indications including lupus nephritis, rheumatoid arthritis, and B-cell lymphomas.